NCT04461041View on ClinicalTrials.gov

Empagliflozin and Cardiac Remodelling in People Without Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

169

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

July 31, 2022

Study Completion Date

July 31, 2022

Conditions
Cardiovascular DiseasesLeft Ventricular Hypertrophy
Interventions
DRUG

Empagliflozin

Single oral tablet

DRUG

Placebo

Placebo tablet manufactured to mimic empagliflozin 10 mg tablet

Trial Locations (4)

M1S 4N6

Diagnostic Assessment Centre (AMS Diagnostics), Toronto

M5B 1W8

St. Michael's Hospital, Toronto

M6B 3H7

North York Diagnostic and Cardiac Centre, Toronto

Unknown

Chang Gung Memorial Hospital, Keelung

Sponsors
All Listed Sponsors
collaborator

Canadian Medical and Surgical Knowledge Translation Research Group

OTHER

collaborator

Boehringer Ingelheim

INDUSTRY

collaborator

Applied Health Research Centre

OTHER

lead

Unity Health Toronto

OTHER